Amiodarone/baricitinib/favipiravirHypothyroidism and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1962卷 / 1期

关键词：

D O I：

10.1007/s40278-023-41695-y

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：25 / 25

相关论文

共 50 条

[41] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[42] Paclitaxel/vemurafenibMyelosuppression and off-label use: case report
Reactions Weekly, 2022, 1888 (1) : 292 - 292
[43] Ketoconazole/MetyraponeHepatotoxicity and off-label use: case report
Reactions Weekly, 2024, 2032 (1) : 228 - 228
[44] RisdiplamPneumonia following off-label use: case report
Reactions Weekly, 2023, 1950 (1) : 348 - 348
[45] Dexamethasone/remdesivirBradycardia and off-label use: case report
Reactions Weekly, 2024, 2028 (1) : 173 - 173
[46] Dexamethasone/ixazomibPneumonitis and off-label use: case report
Reactions Weekly, 2020, 1787 (1) : 185 - 185
[47] PanitumumabSkin rash in an off-label use : case report
Reactions Weekly, 2016, 1610 (1) : 117 - 117
[48] DexamethasoneVarious toxicities and off-label use: case report
Reactions Weekly, 2022, 1904 (1) : 181 - 181
[49] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2023, 1943 (1) : 84 - 84
[50] RivoceranibNeurotoxicity following an off-label use: case report
Reactions Weekly, 2018, 1702 (1) : 232 - 232

← 1 2 3 4 5 →